Opko Health Inc (NYSE:OPK) has tumbled 2.69% during the past week and has dropped 10.84% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 1.52%. Opko Health Inc (NYSE:OPK) has underperformed the index by 11.65% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Opko Health Inc (NYSE:OPK): The stock opened at $9.32 on Friday but the bulls could not build on the opening and the stock topped out at $9.36 for the day. The stock traded down to $9.00 during the day, due to lack of any buying support eventually closed down at $9.05 with a loss of -2.48% for the day. The stock had closed at $9.28 on the previous day. The total traded volume was 4,560,450 shares.
The company shares have dropped -41.61% from its 1 Year high price. On Jul 24, 2015, the shares registered one year high at $17.51 and the one year low was seen on Jan 20, 2016. The 50-Day Moving Average price is $9.99 and the 200 Day Moving Average price is recorded at $9.81.
On the companys insider trading activities, Frost Gamma Investments Trust, CEO of Opko Health, Inc., executed a transaction worth $92,400 on June 16, 2016. A total of 10,000 shares were purchased at an average price of $9.24. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Many analysts have stated their opinion on the company shares. Deutsche Bank maintains its rating on Opko Health Inc (NYSE:OPK). The global brokerage major lowers the current price target from $11 per share to $10 per share. Analysts at the Deutsche Bank have a current rating of Hold on the shares. The rating by the firm was issued on June 16, 2016. Currently the company Insiders own 40.74% of Opko Health Inc shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -0.63% . Institutional Investors own 19.77% of Opko Health Inc shares. During last six month period, the net percent change held by insiders has seen a change of -0.09%.
OPKO Health, Inc. (OPKO) is a biopharmaceutical and diagnostics company. The Company is involved in developing a range of solutions to diagnose, treat and prevent various conditions, including point-of-care tests, laboratory developed tests (LDTs), molecular diagnostics tests, and pharmaceuticals and vaccines. It operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment consists of two operating segments pharmaceutical research and development segment and pharmaceutical operations. Its diagnostics segment consists of pathology operations and point-of-care and molecular diagnostics operations. It owns pharmaceutical operations in Chile, Spain, Mexico, Israel, Uruguay and Brazil. The product pipeline includes several pharmaceutical compounds and technologies in research and development for a range of indications and conditions.